Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Janux Therapeutics, Inc. (JANX) had Consolidated Net Income/Loss of $-21.97M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$10.27M |
|
$-21.97M |
|
-- |
|
$10.27M |
|
$41.96M |
|
$-31.69M |
|
$9.72M |
|
$-21.97M |
|
$-21.97M |
|
$-21.97M |
|
$-21.97M |
|
|
Consolidated Net Income/Loss |
$-21.97M |
$-21.97M |
|
$-31.69M |
|
$-34.11M |
|
62.94M |
|
62.94M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$983.34M |
|
$3.26M |
|
$24.32M |
|
$1.01B |
|
$60.15M |
|
-- |
|
$19.52M |
|
$79.67M |
|
$927.98M |
|
$927.98M |
|
$927.98M |
|
61.08M |
|
| Cash Flow Statement Financials | |
$0.15M |
|
$-30.50M |
|
$5.79M |
|
$53.15M |
|
$28.58M |
|
$-24.57M |
|
$18.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-308.66% |
|
-308.66% |
|
-- |
|
-214.01% |
|
-214.01% |
|
$-0.33M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
68.91 |
|
1.31 |
|
-2.37% |
|
-2.37% |
|
-2.18% |
|
-2.37% |
|
$15.19 |
|
$-0.01 |
|
$0.00 |
|